Clinical Trials Logo

ARDS, Human clinical trials

View clinical trials related to ARDS, Human.

Filter by:

NCT ID: NCT05693051 Completed - ARDS, Human Clinical Trials

Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO

Start date: October 1, 2020
Phase:
Study type: Observational

Prone position ventilation was used 220 times in 44 out of 68 patients with severe COVID-19 induced ARDS treated with VV-ECMO. PPV treated patients did not benefit from PPV and the incidence of PPV related adverse events was high

NCT ID: NCT05598476 Not yet recruiting - ARDS, Human Clinical Trials

Effect of Chest Compression on Respiratory Mechanics in ARDS Patients

Start date: December 2022
Phase:
Study type: Observational

In some ARDS patients, a mild chest compression (5 kg) improves lung compliance. We aim to determine wether such an improvement is due to a better recruitment or to a reduction of overdistension

NCT ID: NCT05525936 Not yet recruiting - Critical Illness Clinical Trials

Echocardiographic Evaluation of RV Injury in the ICU

RECHOicu
Start date: January 1, 2023
Phase:
Study type: Observational

The adequate characterization of RV injury is currently unknown. The hypothesis is that the best characterization of RV injury is the one with the most significant impact on the response to fluids and on the outcome. An RV failure is expected to induce fluid-unresponsiveness and potentially worst outcome. The main objective is to characterize different types of RV injury in critically ill patients by examining their association, including predictive performances, in hemodynamics parameters, ventilation parameters, and clinical outcomes The study will be based on the realisation of an echocardiography within 48 hours following inclusion.

NCT ID: NCT05524558 Recruiting - ARDS, Human Clinical Trials

Assessment of the Hemodynamic Effects of PEEP According to Alveolar Recruitment During the ARDS

Start date: February 1, 2022
Phase:
Study type: Observational

The corner stone of the treatment of ARDS is mechanical ventilation with high levels of positive end-expiratory pressure, also called PEEP. A high level of PEEP is recommended and frequently used. But PEEP can lower cardiac output and contribute to circulatory failure during mechanical ventilation. Nevertheless, in theory, the PEEP-induced pulmonary vascular resistance (PVR) increase could depend on the level of alveolar recruitment, but it has never been proven. Thus, the aim of this study is to determine the relation between the high-PEEP induced PVR and the alveolar recruitment or overdistension.

NCT ID: NCT05492344 Recruiting - Clinical trials for Mechanical Ventilation

Personalized Mechanical Ventilation Guided by UltraSound in Patients With Acute Respiratory Distress Syndrome

Start date: August 9, 2022
Phase: N/A
Study type: Interventional

Rationale Acute respiratory distress syndrome (ARDS) is a frequent cause of hypoxemic respiratory failure with a mortality rate of approximately 30%. The identification of ARDS phenotypes, based on focal or non-focal lung morphology, can be helpful to better target mechanical ventilation strategies of individual patients. Lung ultrasound (LUS) is a non-invasive tool that can accurately distinguish 'focal' from 'non-focal' lung morphology. The investigators hypothesize that LUS-guided personalized mechanical ventilation in ARDS patients will lead to a reduction in 90-day mortality compared to conventional mechanical ventilation.

NCT ID: NCT05491681 Not yet recruiting - ARDS, Human Clinical Trials

AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial

ACE_CARD
Start date: September 15, 2022
Phase: Phase 1
Study type: Interventional

Allogeneic culture-expanded bone marrow-derived human mesenchymal stem cells (MSC) are the subject of the current study as they are supported by preclinical and clinical data for potential to provide a safe and effective treatment for patients with acute respiratory distress.

NCT ID: NCT05442073 Completed - ARDS, Human Clinical Trials

Effect of Initial Empirical PEEP Setting on the Esophageal Pressure-guided PEEP Titration in ARDS

Start date: March 1, 2022
Phase:
Study type: Observational [Patient Registry]

Esophageal manometry was used as surrogate of pleural pressure to titrate positive end-expiratory pressure (PEEP) in ARDS patients. However, Absolute values of esophageal pressure (Pes) could be affected by the PEEP setting. In moderate to severe ARDS patients, the end-expiratory Pes changed differently with PEEP adjustment. and the esophageal phenotypes could be divided into type I and type II. with Type I (ΔPes≥30%ΔPEEP)and Type II(ΔPes<30%ΔPEEP).

NCT ID: NCT05426746 Recruiting - ARDS, Human Clinical Trials

First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100

Start date: July 5, 2022
Phase: Phase 1
Study type: Interventional

ALT-100 is a monoclonal antibody developed by Aqualung Therapeutics Corp. as a treatment for Acute Respiratory Distress Syndrome (ARDS). ARDS can occur as a serious complication in patients with respiratory infections such as COVID-19 and Influenza or have acquired trauma to their lungs. 32 healthy male or female participants between the ages of 18 and 55 years will be enrolled into 4 cohorts of single ascending doses. The doses being investigated are 0.1mg/kg, 0.4mg/kg, 1mg/kg and 4mg/kg administered by intravenous infusion. Participants will be screened within 28 days of study treatment, be admitted to the clinical research unit for 3 nights and attend 7 outpatient visits on study days 8, 15, 22, 29, 60, 90 and 120 respectively. This study will collect data to evaluate safety and tolerability, Pharmacokinetics of ALT-100, Pharmacodynamics of ALT-100 and determine if Anti-drug Antibodies are produced in the participants.

NCT ID: NCT05394961 Completed - COVID-19 Clinical Trials

Factors Associated With Decisions to Withhold or Withdraw Intensive Care

Start date: August 26, 2021
Phase:
Study type: Observational

Medical and socioeconomic data are extracted from the Swedish Intensive Care Registry (SIR), the Swedish National Patient Registry and Statistics Sweden for all adult patients admitted to in Swedish intensive care units between 2014-01-01 and 2020-12-31 with a diagnosis of sepsis and/or acute respiratory distress syndrome (ARDS) and/or coronavirus 19 (COVID-19) infection, and registered in SIR. The impact of demographic and socioeconomic factors on decisions to withhold or withdraw intensive care, and on mortality, are studied and statistically adjusted for level of chronic comorbidity and severity of acute illness.

NCT ID: NCT05384379 Not yet recruiting - ARDS Clinical Trials

Efficacy and Safety Evaluation of BZ371B in ARDS Patients

Start date: November 2022
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety, tolerability and efficacy of BZ371B in intubated patients with severe Acute Respiratory Distress Syndrome.